TICKERNERD
Menu
ELUTELUTHealthcare · Medical Devices

ELUT Stock Forecast: Elutia, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.95
+5.77% on the day

The 1 Wall Street analysts covering Elutia, Inc. hold a median 12-month price target of $5 — +424.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$42.1M
Ticker Nerd rank
27 / 100
Median analyst target
$5.00
Analysts covering
1
Total return, dividends reinvested
1W
+1.4%
1M
+0.4%
YTD
+37.6%
1Y
−56.6%
From 52W high
−60.3%
From 52W low
+88.9%
$0.51
$2.40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELUT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elutia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Issuance
75
Volatility
67
Growth
60
Quality
37
Revisions
32
Value
22
Accruals
13
Momentum
7

Size (84): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELUT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELUT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26ELUTHigh $5.00Median $5.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $5.00Median $5.00High $5.00

The green dot is the last close — the median target sits +424.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Sept 2025Lake StreetMaintainsBuy$8.00 → $6.00
10 Sept 2025Lake StreetMaintainsBuy—
9 May 2025Lake StreetMaintainsBuy—
7 Mar 2025Cantor FitzgeraldReiteratesOverweight—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
6 Sept 2024Cantor FitzgeraldReiteratesOverweight—
8 Aug 2024Cantor FitzgeraldMaintainsOverweight—
21 June 2024Lake StreetMaintainsBuy—
20 June 2024Cantor FitzgeraldMaintainsOverweight—
18 June 2024Cantor FitzgeraldMaintainsOverweight—
10 May 2024Cantor FitzgeraldMaintainsOverweight—
14 Nov 2023Cantor FitzgeraldMaintainsOverweight—
28 Sept 2023Lake StreetInitiatesBuy—
26 Sept 2023Cantor FitzgeraldReiteratesOverweight—
19 Sept 2023Cantor FitzgeraldReiteratesOverweight—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight—
12 May 2023Cantor FitzgeraldMaintainsOverweight$12 → $10
16 Nov 2022Truist SecuritiesMaintainsBuy$8.00 → $10
15 Nov 2022Piper SandlerMaintainsOverweight$9.00 → $11
4 Mar 2022Cowen & Co.MaintainsOutperform$15 → $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELUT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ELUT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Elutia, Inc. (ELUT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.7×

Cheaper than 71% of US stocks

Price / sales
3.5×

Cheaper than 37% of US stocks

Price / book
2.7×

Cheaper than 38% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−11.6%

Higher than 14% of US stocks

Earnings growth (YoY)
−48.4%

Higher than 10% of US stocks

Gross margin
57.9%

Higher than 72% of US stocks

Operating margin
−243.1%

Higher than 10% of US stocks

Net margin
426.9%

Higher than 99% of US stocks

Returns & dividend
Return on equity
192.9%

Higher than 98% of US stocks

Return on assets
−34.7%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ELUT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ELUTElutia, Inc.$42.1M
27
NSPRInspireMD, Inc.$42.1M
53
QTIQT Imaging Holdings, Inc.$42.6M
24
PAVMPAVmed, Inc.$41.4M
15
SNWVSANUWAVE Health, Inc.$39.5M
51
XTNTXtant Medical Holdings, Inc.$45.5M
83
BDMDBaird Medical Investment Holdings Ltd.$49.0M
10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elutia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELUT news & analysis

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

GlobeNewsWire · 18 Aug 2026neutral

Cellution Biologics announced it has completed its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. The transaction was announced in a GlobeNewsWire release dated August 18, 2026.

Why it matters — The completion of this divestiture marks a structural change in Elutia's business, as it has transferred ownership of its SimpliDerm ADM product line to Cellution Biologics.

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

GlobeNewsWire · 18 Aug 2026positive

Elutia completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics, receiving $8 million in cash at closing with up to $3 million in additional milestone payments over 18 months. The divestiture focuses Elutia's resources on developing and commercializing its NXT-41x antibiotic-eluting biomatrix, with clearance expected in the first half of 2027.

Why it matters — This divestiture adds cash to Elutia's balance sheet and concentrates the company's resources on advancing NXT-41x toward commercial launch.

Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of Elutia Inc.'s Q2 2026 earnings call, providing a record of management's discussion of the company's quarterly results.

Why it matters — ELUT watchers can review the full earnings call transcript for management commentary on the company's latest quarterly performance.

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

GlobeNewsWire · 13 Aug 2026positive

Elutia announced it has secured up to $26 million in capital without an equity offering to fund NXT-41x through commercial launch, and reported its second quarter 2026 financial results. The company also provided a business update, including surgeon survey data and expected FDA clearance timelines for NXT-41 (4Q 2026) and NXT-41x (1H 2027).

Why it matters — ELUT watchers would care because the funding secures NXT-41x through commercial launch without dilutive equity, and the company reports strong surgeon adoption interest ahead of upcoming FDA clearance decisions.

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

GlobeNewsWire · 13 Aug 2026positive

Elutia announced a $15 million growth capital financing agreement with Avenue Capital Group. The first $10 million was funded at closing, with an additional $5 million tranche to be released upon FDA 510(k) clearance of Elutia's NXT-41x antibiotic-eluting biomatrix, targeting post-operative infections in the plastic and reconstructive surgery market.

Why it matters — ELUT watchers would care because the loan funds the commercialization of NXT-41x without an equity offering, preserving shareholder value as the product targets a $1.5 billion market with high post-operative infection rates.

FAQ

Frequently asked questions about ELUT stock

What is the ELUT stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Elutia, Inc. have a median 12-month price target of $5, with estimates ranging from $5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELUT stock a buy right now?

Of the 1 analysts covering Elutia, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elutia, Inc. 27 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELUT?

As at 22 Aug 2026, Elutia, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will ELUT stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +424.2% from the last close, and Ticker Nerd's factor model ranks Elutia, Inc. 27 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELUT stock forecast for 2030?

No analyst covering Elutia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

How has ELUT stock performed over the past year?

Elutia, Inc. returned -56.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elutia, Inc. do?

Elutia Inc. operates within the specialized sector of biotechnology and medical technologies, focusing on the development and commercialization of drug-eluting biomaterials.

What is the latest news on ELUT?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.". Cellution Biologics announced it has completed its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. The transaction was announced in a GlobeNewsWire release dated August 18, 2026.

Company

About Elutia, Inc.

Elutia Inc. operates within the specialized sector of biotechnology and medical technologies, focusing on the development and commercialization of drug-eluting biomaterials. These innovative products are designed to deliver active pharmaceutical ingredients directly to the target tissues, enhancing therapeutic efficacy and reducing systemic side effects. Elutia’s offerings have significant applications in areas such as wound care, cardiovascular treatments, and orthopedic interventions. This targeted delivery system allows for more precise treatment modalities in various medical specialties, facilitating improved patient outcomes. As part of the burgeoning field of precision medicine, Elutia Inc. plays a crucial role by harnessing advanced biomaterial technologies that could transform traditional therapeutic approaches. The company’s contributions to medical innovation highlight its importance as an influencer in the healthcare industry, constantly pushing the boundaries for more effective and safer therapeutic solutions. Positioned at the intersection of biotechnology and drug delivery systems, Elutia Inc. is pivotal in developing solutions that support the evolving demands of modern medicine.

CEO Dr. C. Randal Mills Ph.D. · 25 employees · United States · https://elutia.com